◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › NTRA

Natera Inc (NTRA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DIAGNOSTICS & RESEARCH · DATA UPDATED 2026-07-21

Natera Inc (NTRA) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in Austin, United States with about 6,135 employees. Its market capitalization is roughly $38 billion. In the fiscal year ended 2025-12-31, NTRA reported $2.3B in revenue and ($208M) in net income.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.

Interactive charts & full statements → Open the NTRA valuation workbench →

NTRA Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$2.5B	$2.3B	$1.7B	$1.1B	$820M	$625M	$391M	$302M	$258M	$211M	$217M	$190M	$159M	$55M	$14M
Gross Profit	$1.6B	$1.5B	$1.0B	$493M	$364M	$307M	$187M	$127M	$92M	$71M	$82M	$78M	$81M	$18M	$3M
Gross Margin %	65.2%	64.8%	60.3%	45.5%	44.4%	49.1%	47.9%	42.0%	35.5%	33.8%	37.5%	40.7%	50.8%	32.4%	21.7%
Operating Income (EBIT)	($324M)	($310M)	($222M)	($446M)	($541M)	($468M)	($216M)	($116M)	($115M)	($134M)	($96M)	($60M)	$1M	($25M)	($19M)
Operating Margin %	-13.0%	-13.4%	-13.1%	-41.2%	-66.0%	-74.9%	-55.3%	-38.5%	-44.5%	-63.5%	-44.5%	-31.4%	0.4%	-45.8%	-134.8%
Net Income	($226M)	($208M)	($190M)	($435M)	($548M)	($472M)	($230M)	($125M)	($128M)	($136M)	($96M)	($70M)	($5M)	($37M)	($76M)
Net Margin %	-9.0%	-9.0%	-11.2%	-40.2%	-66.8%	-75.4%	-58.8%	-41.3%	-49.7%	-64.6%	-44.1%	-36.9%	-3.2%	-67.3%	-534.5%
EBITDA	($224M)	($221M)	($148M)	($383M)	($507M)	($452M)	($206M)	($104M)	($107M)	($126M)	($93M)	($61M)	$4M	($23M)	($18M)
Earnings Per Share (EPS)	$-1.63	$-1.52	$-1.53	$-3.78	$-5.57	$-5.21	$-2.84	$-1.79	$-2.22	$-2.54	$-1.86	$-1.47	$-0.14	$-1.01	$-24.37
Shares Outstanding (M)	142M	137M	125M	115M	98M	91M	81M	70M	58M	54M	52M	48M	37M	37M	3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NTRA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$697M	$666M	$592M	$547M	$502M	$476M	$440M	$413M
Gross Profit	$451M	$447M	$384M	$347M	$317M	$300M	$272M	$243M
Gross Margin %	64.8%	67.1%	64.9%	63.5%	63.2%	62.9%	61.8%	58.8%
Operating Income (EBIT)	($94M)	($23M)	($98M)	($110M)	($79M)	($65M)	($39M)	($44M)
Operating Margin %	-13.4%	-3.4%	-16.5%	-20.2%	-15.8%	-13.6%	-8.9%	-10.6%
Net Income	($85M)	$47M	($88M)	($101M)	($67M)	($54M)	($32M)	($37M)
Net Margin %	-12.2%	7.1%	-14.8%	-18.5%	-13.3%	-11.3%	-7.2%	-9.1%
EBITDA	($65M)	$8M	($76M)	($90M)	($57M)	($46M)	($20M)	($26M)
Earnings Per Share (EPS)	$-0.60	$0.35	$-0.64	$-0.74	$-0.50	$-0.43	$-0.26	$-0.30
Shares Outstanding (M)	142M	137M	137M	136M	135M	125M	124M	123M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NTRA Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cash from Operations (CFO)	$211M	$215M	$136M	($247M)	($432M)	($335M)	($183M)	($63M)	($71M)	($98M)	($74M)	($38M)	$10M	($24M)	($15M)
Capital Expenditures (CapEx)	$119M	$106M	$66M	$39M	$48M	$41M	$20M	$5M	$4M	$10M	$23M	$8M	$10M	$8M	$5M
Free Cash Flow (FCF)	$92M	$109M	$69M	($286M)	($479M)	($376M)	($202M)	($68M)	($74M)	($108M)	($97M)	($46M)	$1M	($32M)	($19M)
FCF Margin %	3.7%	4.7%	4.1%	-26.4%	-58.4%	-60.2%	-51.7%	-22.6%	-28.9%	-51.0%	-44.8%	-24.0%	0.3%	-58.7%	-136.8%
Dividends Paid	—	—	—	—	$30M	—	$7M	—	—	$0M	$3M	$0M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NTRA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$40M	$74M	$59M	$38M	$44M	$53M	$52M	$4M
Capital Expenditures (CapEx)	$22M	$36M	$35M	$26M	$22M	$18M	$16M	$12M
Free Cash Flow (FCF)	$18M	$38M	$24M	$12M	$23M	$35M	$35M	($8M)
FCF Margin %	2.6%	5.7%	4.1%	2.1%	4.5%	7.3%	8.1%	-1.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NTRA Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Assets	$2.6B	$2.5B	$1.7B	$1.4B	$1.4B	$1.2B	$932M	$583M	$268M	$215M	$211M	$265M	$124M	$60M	$13M
Cash & Cash Equivalents	$1.1B	$1.1B	$946M	$642M	$466M	$84M	$49M	$62M	$46M	$13M	$15M	$29M	$87M	$30M	$6M
Total Liabilities	$840M	$796M	$465M	$676M	$689M	$583M	$446M	$304M	$236M	$189M	$104M	$80M	$295M	$231M	$139M
Total Debt (Short + Long-Term)	$95M	$96M	$91M	$375M	$370M	$336M	$260M	$130M	$124M	$123M	$50M	$42M	$27M	$24M	$132M
Total Shareholders' Equity	$1.8B	$1.7B	$1.2B	$765M	$706M	$653M	$486M	$279M	$32M	$25M	$106M	$185M	($171M)	($172M)	($126M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NTRA viewer.

← NTR All stocks NTRB →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.